within Pharmacolibrary.Drugs.ATC.A;

model A07EC02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.29,
    Cl             = 7.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0083,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.037333333333333336,
    Tlag           = 24.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A07EC02_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an anti-inflammatory drug used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. It is approved and widely used today, primarily for induction and maintenance of remission in these conditions.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic estimates for patients with inflammatory bowel disease taking oral delayed-release mesalazine tablets.</p><h4>References</h4><ol><li><p>Zhang, Y, et al., &amp; Zuo, Z (2022). Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 346 275–288. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2022.04.024\">10.1016/j.jconrel.2022.04.024</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35461968/\">https://pubmed.ncbi.nlm.nih.gov/35461968</a></p></li><li><p>De Vos, M (2000). Clinical pharmacokinetics of slow release mesalazine. <i>Clinical pharmacokinetics</i> 39(2) 85–97. DOI:<a href=\"https://doi.org/10.2165/00003088-200039020-00001\">10.2165/00003088-200039020-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10976656/\">https://pubmed.ncbi.nlm.nih.gov/10976656</a></p></li><li><p>Prakash, A, &amp; Markham, A (1999). Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn&#x27;s disease. <i>Drugs</i> 57(3) 383–408. DOI:<a href=\"https://doi.org/10.2165/00003495-199957030-00013\">10.2165/00003495-199957030-00013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10193690/\">https://pubmed.ncbi.nlm.nih.gov/10193690</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A07EC02_1;
